Tenaya Therapeutics is a clinical-stage biotechnology company developing genetic medicines to treat heart disease by addressing its underlying genetic causes. The company's pipeline includes AAV9-based gene therapies for rare cardiomyopathies and a small-molecule HDAC6 inhibitor in development, along with early-stage programs using cellular regeneration, gene editing, and gene silencing approaches. Tenaya generates revenue through research collaborations and milestone payments while working toward commercialization of its rare disease programs through an internal salesforce and partnerships with larger pharmaceutical companies for more prevalent indications.